SenzaGen Dividenda 2024

Detalji o dividendama

Razumevanje dividendnih isplata od SenzaGen

Dividende od SenzaGen su deo profita kompanije koji se distribuira akcionarima. One su ključni indikator finansijskog zdravlja kompanije i atraktivnosti za investitore. Dividende pružaju investitorima stabilan izvor prihoda, pored dobiti koja se možda može ostvariti prodajom akcija po višoj ceni od kupovne.

Poređenje iz godine u godinu

Analiza isplata dividendi od SenzaGen tokom godina može istaći profitabilnost i stabilnost kompanije. Konstantno ili rastuće isplate dividendi mogu ukazivati na finansijski zdravu kompaniju sa predvidivim profitom, dok fluktuacije ili smanjenja dividendi mogu signalizirati osnovne finansijske ili operativne izazove.

Uticaj na investicije

Isplate dividendi od SenzaGen su suštinski faktor za investitore orijentisane na prihod. Robusna isplata dividendi može povećati privlačnost akcije i pružiti redovni prihod pored potencijalnih kapitalnih dobitaka. Ona može takođe pokazati poverenje kompanije u njene buduće profite i time biti značajan faktor za odlučivanje o investicijama.

Interpretacija fluktuacija dividendi

Promene u dividendama od SenzaGen mogu proistići iz promena u profitima kompanije, finansijskoj politici ili strategijama reinvestiranja. Povećanje dividendi često signalizira finansijsku stabilnost, dok smanjenje može ukazivati na potrebu da se sačuva gotovina ili da se profiti reinvestiraju radi podsticanja rasta, pri čemu svaki scenario ima različite posledice za investitore.

SenzaGen Aktienanalyse

Шта ради SenzaGen?

SenzaGen AB is a Swedish biotechnology company that specializes in the development and marketing of innovative and reliable tests for assessing allergenicity. Founded in 2010 by leading experts from the academic and industry sectors, the company has become a significant player in the field of toxicology. Current methods for assessing allergenicity, such as asthma, eczema, and allergic reactions, are often inaccurate and require the use of animals, which is ethically questionable and expensive. SenzaGen AB has developed a wide range of tests based on biomolecular technologies that use human cells to assess the allergenic reactivity of chemicals and products. These tests are accurate, cost-effective, and meet the current requirements of regulatory authorities and the industry. The company is headquartered in Lund, Sweden, and currently employs about 20 people. SenzaGen AB is a leader in the development of in vitro methods for evaluating allergenicity and utilizes various platform technologies such as gene expression and proteomics analysis, as well as the use of immune cells and keratinocytes. SenzaGen AB's Microarray technology platform, based on DNA-based tests, has been recognized by the European Chemicals Agency (ECHA) as suitable for assessing allergenic reactivity. The company has also partnered with the US biotechnology company In vitro International (IVI) to distribute its allergen tests in the North American market. SenzaGen AB has developed a wide range of products that can be used in various sectors such as cosmetics, food, chemicals, and pharmaceuticals. AllergoDx™ is a test system used by the pharmaceutical and chemical industries to determine the allergenic reactivity of chemicals. GARD™ (Genomic Allergen Rapid Detection) is a rapid test used in the cosmetics and food industries to determine the allergenic reactivity of new products and avoid costly animal testing. GARDskin™ is a skin test used to determine the reactivity of substances that come into contact with the skin, primarily in the chemicals and pharmaceutical industries. Other products in the company's pipeline include GARDpotency™ and GARDair™, which are intended for assessing allergic reactions in industrial and occupational environments. SenzaGen AB has experienced significant growth in recent years and plans to expand its product range and strengthen its market position. The company's business model is based on selling tests and services to chemical, pharmaceutical, food, and cosmetic companies worldwide. Through its innovative technologies and willingness to collaborate with customers, the company has taken a leadership role in toxicology. SenzaGen AB is committed to an ethical and responsible corporate philosophy focused on sustainability and environmental protection. The company has clear goals to meet the growing demand for reliable and ethical testing methods to minimize the impact of chemicals on humans and the environment. SenzaGen je jedna od najpopularnijih kompanija na Eulerpool.com.

Često postavljana pitanja o SenzaGen akciji

Kolika je dividenda koju isplaćuje SenzaGen?

U poslednjih 12 meseci, SenzaGen je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, SenzaGen će verovatno isplatiti dividendu od 0 SEK.

Kolika je dividendna prinosa za SenzaGen?

Dividendski prinos od SenzaGen trenutno iznosi .

Kada SenzaGen isplaćuje dividendu?

SenzaGen isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Koliko je sigurna dividenda od SenzaGen?

SenzaGen je isplaćivao dividendu svake godine u poslednjih 0 godina.

Kolika je dividenda kompanije SenzaGen?

Za narednih 12 meseci očekuju se dividende u iznosu od 0 SEK. To odgovara dividendnom prinosu od 0 %.

U kom sektoru se nalazi SenzaGen?

SenzaGen se svrstava u sektor 'Zdravlje'.

Wann musste ich die Aktien von SenzaGen kaufen, um die vorherige Dividende zu erhalten?

Da biste primili poslednju dividendu od SenzaGen od 17. 9. 2024. u iznosu od 0 SEK, morali ste da imate akciju u depou pre Ex-dana 17. 9. 2024..

Kada je SenzaGen poslednji put isplatio dividendu?

Isplata poslednje dividende izvršena je 17. 9. 2024..

Kolika je bila dividenda od SenzaGen u godini 2023?

U godini 2023 kompanija SenzaGen je isplatila 0 SEK kao dividende.

U kojoj valuti SenzaGen isplaćuje dividendu?

Dividende od SenzaGen se isplaćuju u SEK.